EMSY

EMSY is a nuclear chromatin-associated protein that couples transcriptional repression to the control of genome stability, functioning as a central effector of the "BRCAness" phenotype (PMID:14651845, PMID:34963055). It binds directly to the BRCA2 region encoded by exon 3, silencing the transcriptional activation potential of that domain, and localizes to sites of DNA damage (PMID:14651845); through this interaction EMSY overexpression cripples BRCA2/RAD51-dependent homologous recombination repair independently of transcription, plausibly by displacing RPA and PALB2 from a shared BRCA2 surface, and produces chromosomal instability resembling BRCA2 loss (PMID:21409565, PMID:16145051). EMSY engages the chromatin machinery through an N-terminal ENT domain that homodimerizes and an adjacent non-canonical motif that binds two HP1beta chromoshadow-domain dimers, assembling a defined EMSY-HP1beta architecture (PMID:16615912, PMID:15978617, PMID:15947784). It nucleates H3K4me3-demethylase repressor complexes — recruiting KDM5B via ETS-1 to silence the antimetastatic miR-31 (PMID:24582497), and assembling with KDM5A and SIN3B and being targeted to active, H3K4me3-marked promoters by ZNF131 (PMID:26841866) — and competitively inhibits KDM5B catalytic activity to reshape methionine metabolism and stem-cell self-renewal (PMID:38290515). EMSY-mediated repression is gated by phosphorylation: Akt1 phosphorylates Ser209 to relieve repression of interferon-stimulated genes and enable an antiviral response, while PKA phosphorylates Thr207 to drive suppression of DNA repair (PMID:22315412, PMID:28099152). EMSY protein levels are restrained by KEAP1-directed ubiquitin-mediated degradation; KEAP1 loss stabilizes EMSY, generating HR-repair defects, PARP-inhibitor sensitivity, and suppression of the type I interferon response that fosters cancer immune evasion (PMID:34963055). EMSY additionally interacts with beta-catenin to activate TCF signaling and LDHA-driven glycolysis (PMID:25510665, PMID:41023769), and is required for normal vertebrate development and for restraint of the skin barrier program (PMID:21056705, PMID:31158401).

1. 2003 High

   Established EMSY as a BRCA2-binding nuclear protein, framing how a non-mutated BRCA2 pathway could be inactivated and linking EMSY to both transcription and DNA repair.

   Evidence Co-IP, transcriptional reporter assays, and localization to DNA damage sites

   PMID:14651845

   Open questions at the time

   • Did not define the structural basis of any interaction
   • Did not establish whether repression and repair functions are separable
2. 2005 High

   Resolved the architecture of EMSY's N-terminal module, showing the ENT domain forms a low-micromolar homodimer and that an adjacent motif binds HP1beta, defining how EMSY docks onto chromatin machinery.

   Evidence X-ray crystallography (2.0 Å), NMR, biophysical and mutagenesis analyses of ENT dimerization and HP1beta-CSD binding

   PMID:15947784 PMID:15978617

   Open questions at the time

   • Did not connect the structural module to a transcriptional or repair output in cells
   • Functional consequence of dimerization untested in vivo
3. 2005 Medium

   Showed that a BRCA2-interacting EMSY fragment is sufficient to induce chromosomal instability, providing the first phenotypic link between EMSY overexpression and a BRCA2-loss-like state.

   Evidence Lentiviral overexpression of truncated EMSY, metaphase analysis, mitomycin C challenge in breast epithelial cells

   PMID:16145051

   Open questions at the time

   • Used a truncated construct, not full-length protein
   • Single lab; mechanism of instability not resolved
4. 2006 High

   Determined the high-resolution structure of the EMSY-HP1beta CSD complex, revealing a 2:2 binding mode that diverges from the canonical PXVXL motif.

   Evidence X-ray crystallography at 1.8 Å

   PMID:16615912

   Open questions at the time

   • Cellular consequence of the non-canonical mode not tested
   • Stoichiometry with full repressor complexes unaddressed
5. 2011 Medium

   Separated EMSY's repair function from its transcriptional function, showing overexpression suppresses BRCA2/RAD51 HR repair, likely by competing with RPA and PALB2 at a shared BRCA2 surface.

   Evidence DR-GFP recombination assay with EMSY overexpression

   PMID:21409565

   Open questions at the time

   • Competition with RPA/PALB2 inferred, not directly demonstrated
   • Single method, single lab
6. 2012 High

   Identified Akt1-specific phosphorylation of EMSY at Ser209 as a switch that relieves repression of interferon-stimulated genes, embedding EMSY in antiviral signaling.

   Evidence In vitro kinase assay, ChIP at ISG promoters, gain/loss-of-function with antiviral readouts against HSV-1 and VSV

   PMID:22315412

   Open questions at the time

   • In vivo relevance of Ser209 phosphorylation not established
   • How phosphorylation alters chromatin binding mechanistically unclear
7. 2014 Medium

   Defined EMSY as a recruitable corepressor that delivers an H3K4me3 demethylase to specific promoters and links it to beta-catenin oncogenic signaling.

   Evidence ChIP and Co-IP placing EMSY/KDM5B at the miR-31 promoter via ETS-1; Co-IP with beta-catenin, TCF reporter, knockdown and xenograft assays

   PMID:24582497 PMID:25510665

   Open questions at the time

   • beta-catenin interaction shown by Co-IP without structural mapping
   • Generality of ETS-1/KDM5B recruitment beyond miR-31 untested
8. 2016 High

   Mapped EMSY's native repressor complex (KDM5A/SIN3B) and its recruitment by ZNF131 to active promoters, refining EMSY as a chromatin regulator that frequently correlates with target gene activity.

   Evidence Quantitative interaction proteomics, ChIP-seq, and EMSY knockout with rescue

   PMID:26841866

   Open questions at the time

   • Reconciliation of positive correlation with repressor recruitment incomplete
   • Substoichiometric ZNF131 role not structurally defined
9. 2017 Medium

   Showed PKA phosphorylates EMSY at Thr207 to drive BRCA2-independent suppression of DNA repair, adding a second kinase input controlling EMSY's genome-stability function.

   Evidence DR-GFP and RAD51 foci assays, in vitro PKA kinase assay, immunoprecipitation

   PMID:28099152

   Open questions at the time

   • Mechanism by which T207 phosphorylation alters repair unclear
   • Single lab; physiological PKA trigger not defined
10. 2021 High

    Identified KEAP1 as the degron controlling EMSY abundance and showed that KEAP1 loss stabilizes EMSY to produce BRCAness, PARP-inhibitor sensitivity, and type I interferon suppression driving immune evasion.

    Evidence KEAP1 loss-of-function, ubiquitin-degradation assays, HRR and PARP-inhibitor sensitivity assays, interferon readouts, STING agonist rescue

    PMID:34963055

    Open questions at the time

    • Degron motif on EMSY not mapped
    • Relationship between KEAP1-axis and kinase phospho-switches unresolved
11. 2024 Medium

    Demonstrated that EMSY can act as a direct competitive inhibitor of KDM5B catalytic activity, linking its chromatin role to methionine metabolism and stem-cell self-renewal.

    Evidence Multiomics, Co-IP with KDM5B Jmjc domain, H3K4 methylation and methionine-deprivation functional assays

    PMID:38290515

    Open questions at the time

    • Reconciliation with EMSY-KDM5A/SIN3B complex recruitment unclear
    • Single lab; structural basis of Jmjc competition not solved
12. 2025 Medium

    Extended the EMSY/beta-catenin axis to metabolic reprogramming, showing EMSY promotes LDHA transcription and glycolysis in ovarian cancer.

    Evidence Co-IP with beta-catenin, LDHA knockdown rescue, lactate and glycolysis assays

    PMID:41023769

    Open questions at the time

    • Direct vs indirect promoter occupancy at LDHA not established
    • Single lab

• How the multiple inputs converging on EMSY — KEAP1-mediated stability, Akt1/PKA phosphorylation, and partner choice between repressor complexes versus KDM5B inhibition — are integrated to select between DNA-repair suppression, interferon repression, and oncogenic transcription remains unresolved.
• No unified model linking phospho-switches to KEAP1 abundance control
• Context-dependence across tissues and tumor types not systematically dissected
• No structure of full-length EMSY in any functional complex